Abraxane Randomized Trial Needed For Adjuvant Breast Cancer, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC votes in favor of Abraxis conducting an additional clinical trial to extend Abraxane’s indication from metastatic breast cancer into the adjuvant setting during a Sept. 7 meeting.